Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AKR-001
AKR-001
Akero’s success gives a new Nash mechanism hope
EP Vantage
Thu, 04/2/20 - 11:01 am
Akero Therapeutics
NASH
AKR-001
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
EP Vantage
Sat, 01/18/20 - 07:34 pm
Bayer
Merck
vericiguat
heart failure
AKR-001
Akero Therapeutics
clinical trials
NASH
Upstart Akero continues its swoosh into NASH space with $70M windfall round
Endpoints
Wed, 12/12/18 - 07:01 pm
Akero Therapeutics
NASH
AKR-001
Akero picks up $65M to advance Amgen-licensed NASH drug
Fierce Biotech
Mon, 06/25/18 - 09:28 am
Akeron Therapeutics
NASH
Amgen
AKR-001